JMJenna Morgan

Jenna Morgan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jenna Morgan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Kathryn Thomas

    Yorkshire Deanery

    4 shared publications
  • Heather Lee-Robichaud

    Northern General Hospital Department of General Surgery Herries Road Sheffield South Yorkshire UK S5 7AU

    3 shared publications
  • Richard L Nelson

    Northern General Hospital Department of General Surgery Herries Road Sheffield South Yorkshire UK S5 7AU

    3 shared publications
  • Sarah Braungart

    Yorkshire Deanery

    2 shared publications
  • H.N. Khan

    Department of General Surgery, Rotherham General Hospital

    1 shared publication
  • Karen A Collins

    Sheffield Hallam University Centre for Health and Social Care Research Montgomery House 32 Collegiate Crescent Sheffield UK S10 2BP

    1 shared publication

Latest Publications

  • Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)

    by Jenna Morgan, Lynda Wyld, Karen A Collins, Malcolm W Reed

    Background Several studies have evaluated the clinical effectiveness of endocrine therapy alone in women aged 70 years or over with operable breast cancer and who are fit for surgery. Objectives To systematically review the evidence for the clinical effectiveness of surgery (with or without adjuvant endocrine therapy) in comparison to primary endocrine therapy in the treatment of operable breast cancer in women aged 70 years and over, both in terms of local progression and mortality. Search methods We conducted an updated search of the Cochrane Breast Cancer Group's Specialised Register (27th March 2013) and new searches of the Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 3), MEDLINE, EMBASE, the World Health Organization's International Clinical Trials Registry Platform (apps.who.int/trialsearch/) and www.clinicaltrials.gov, using the search terms 'early breast cancer', 'endocrine therapy', 'psychosocial' or 'surgery'. Selection criteria Randomised trials comparing surgery, with or without adjuvant endocrine therapy, to primary endocrine therapy in the management of women aged 70 years or over with early breast cancer and who were fit for surgery. Data collection and analysis We assessed studies for eligibility and quality, and two review authors independently extracted data from published trials. We derived hazard ratios for time‐to‐event outcomes, where possible, and used a fixed‐effect model for meta‐analysis. We extracted toxicity and quality‐of‐life data, where present. Where outcome data were not available, we contacted trialists and requested unpublished data. Main results We identified seven eligible trials, of which six had published time‐to‐event data and one was published only in abstract form with no usable data. The quality of the allocation concealment was adequate in three studies and unclear in the remainder. In each case the endocrine therapy used was tamoxifen. Data, based on an estimated 1081 deaths in 1571 women, did not show a statistically significant difference in favour of either surgery or primary endocrine therapy in respect of overall survival. However, there was a statistically significant difference in terms of progression‐free survival, which favoured surgery with (474 participants) or without endocrine therapy (164 participants). The hazard ratios (HRs) for overall survival were: HR 0.98 (95% confidence interval (CI) 0.81 to 1.20, P = 0.85; 3 trials, 495 participants) for surgery alone versus primary endocrine therapy; HR 0.86 (95% CI 0.73 to 1.00, P = 0.06; 3 trials, 1076 participants) for surgery plus endocrine therapy versus primary endocrine therapy. The HRs for progression‐free survival were: HR 0.55 (95% CI 0.39 to 0.77, P = 0.0006) for surgery alone versus primary endocrine therapy; HR 0.65 (95% CI 0.53 to 0.81, P = 0.0001) for surgery plus endocrine therapy versus primary endocrine therapy (each comparison based on only one trial). Tamoxifen‐related adverse effects included hot flushes, skin rash, vaginal discharge, indigestion, breast pain, sleepiness, headache, vertigo, itching, hair loss, cystitis, acute thrombophlebitis, nausea, and indigestion. Surgery‐related adverse effects included paraesthesia on the ipsilateral arm and lateral thoracic wall in those who had axillary clearance. One study suggested that those undergoing surgery suffered more psychosocial morbidity at three months post‐surgery, although this difference had disappeared by two years. Authors' conclusions Primary endocrine therapy should only be offered to women with oestrogen receptor (ER)‐positive tumours who are unfit for surgery, at increased risk of serious surgical or anaesthetic complications if subjected to surgery, or who refuse surgery. In a cohort of women with significant co‐morbid disease and ER‐positive tumours it is possible that primary endocrine therapy may be a superior option to surgery. Trials are needed to evaluate the clinical effectiveness of aromatase inhibitors as primary therapy for an infirm older population with ER‐positive tumours.


  • Transparent cap colonoscopy versus standard colonoscopy: a systematic review and meta-analysis

    by Jenna L. Morgan, Kathryn Thomas, Sarah Braungart, Richard L. Nelson

    Due to the increasing demand for colonoscopy, devices to advance examination techniques are highly sought after. Several studies have examined the use of a transparent cap attached to the tip of the colonoscope, but the data are inconsistent. The aim of our study was to establish whether transparent cap colonoscopy is beneficial in the improvement of caecal intubation rate, time and polyp detection. We undertook a systematic review and meta-analysis in the form of a Cochrane review to evaluate these outcomes. We included fourteen randomised controlled trials that have been published to date. Transparent cap colonoscopy demonstrates a significant reduction in caecal intubation time, by an average of 48 s, when compared to standard colonoscopy. There was no significant difference in caecal intubation rate or polyp detection between the two groups. Despite a significant difference in caecal intubation time, the clinical significance of the transparent cap remains to be seen. We believe further research is needed to investigate this adjunct.


  • Transparent Cap Colonoscopy versus Standard Colonoscopy to Improve Caecal Intubation

    by Jenna Morgan, Kathryn Thomas, Heather Lee-Robichaud, Richard L Nelson, Sarah Braungart

    Background Colonoscopy is considered the gold‐standard investigation for screening and diagnosis of colorectal cancer. It is also becoming increasingly desirable for assessment, management, diagnosis and follow‐up of other colorectal diseases, such as inflammatory bowel diseases and acute diverticulitis. Hence, due to the increasing demand for colonoscopy, devices to advance examination techniques are highly sought‐after and the colonoscope with the transparent cap could be one of these. Objectives To identify and review all relevant data in order to determine whether colonoscopy with a transparent cap is a more effective diagnostic tool than colonoscopy. Search methods We searched the MEDLINE, EMBASE and CINAHL databases, and the Cochrane Central Register of Controlled Trials for all randomised controlled trials (RCTs) comparing the use of colonoscopy with a transparent cap with standard colonoscopy. Selection criteria Studies were included if they were randomised controlled trials which compared the use of colonoscopy with a transparent cap with standard colonoscopy. Data collection and analysis Data on study methods, participants, interventions used and outcomes measured was extracted from each study. Data was entered into the Cochrane Review Manager software (RevMan 5.0, 2008) and analysed using Cochrane MetaView. Main results In the present meta‐analysis, we considered 14 randomised controlled trials so far published. The findings of our work indicate that colonoscopy with transparent cap has a faster caecal intubation time when compared with standard colonoscopy. Reviewing studies individually would also seem to favour colonoscopy with transparent cap for polyp detection rate and pain during procedure but due to lack of comparable data meta‐analysis was not feasible. Authors' conclusions This review suggests that a transparent cap on the end of the colonoscope may give a marginally faster caecal intubation time compared with standard colonoscopy. It also suggests that there is a better polyp detection rate and less pain with the cap. However, the authors feel that further randomised controlled trials in this area would provide more clinically significant information on this adjunct to colonoscopy.


  • Transparent Cap Colonoscopy versus Standard Colonoscopy for Investigation of Gastrointestinal Tract Conditions

    by Jenna Morgan, Kathryn Thomas, Heather Lee-Robichaud, Richard L Nelson

    Background Colonoscopy is considered the gold‐standard investigation for screening and diagnosis of colorectal cancer. It is also becoming increasingly desirable for assessment, management, diagnosis and follow‐up of other colorectal diseases, such as inflammatory bowel diseases and acute diverticulitis. Hence, due to the increasing demand for colonoscopy, devices to advance examination techniques are highly sought‐after and the colonoscope with the transparent cap could be one of these. Objectives To identify and review all relevant data in order to determine whether colonoscopy with a transparent cap is a more effective diagnostic tool than colonoscopy. Search methods We searched the MEDLINE, EMBASE and CINAHL databases, and the Cochrane Central Register of Controlled Trials for all randomised controlled trials (RCTs) comparing the use of colonoscopy with a transparent cap with standard colonoscopy. Selection criteria Studies were included if they were randomised controlled trials which compared the use of colonoscopy with a transparent cap with standard colonoscopy. Data collection and analysis Data on study methods, participants, interventions used and outcomes measured was extracted from each study. Data was entered into the Cochrane Review Manager software (RevMan 5.0, 2008) and analysed using Cochrane MetaView. Main results In the present meta‐analysis, we considered for the first time all five randomised controlled trials so far performed. The findings of our work indicate that colonoscopy with transparent cap has a faster caecal intubation time when compared with standard colonoscopy. Reviewing studies individually would also seem to favour colonoscopy with transparent cap for polyp detection rate and pain during procedure but due to lack of comparable data meta‐analysis was not feasible. Authors' conclusions This review suggests that a transparent cap on the end of the colonoscope may give a marginally faster caecal intubation time compared with standard colonoscopy. It also suggests that there is a better polyp detection rate and less pain with the cap. However, the authors feel that further randomised controlled trials in this area would provide more clinically significant information on this adjunct to colonoscopy.


  • Transparent Cap Colonoscopy versus Standard Colonoscopy for Investigation of Gastrointestinal Tract Conditions

    by Jenna Morgan, Kathryn Thomas, Heather Lee-Robichaud, Richard L Nelson

  • Oesophageal stenting in a district general hospital

    by J.L. Morgan, H.N. Khan, M.M. Lambertz